RSV poses rising risks for older adults. AMR Clinical sites supported this phase 3 trial for an investigational RSVPreF3 vaccine. With data from over 1,600 participants, researchers found that the vaccine was well tolerated, with most adverse events being mild, moderate, and short-lived.
Read this publication to explore:
- Rates of local and systemic reactions post-vaccination
- Incidence of serious adverse events and immune-mediated responses
- What these interim data mean for RSV vaccine development in older populations